Measuring dabigatran with the dilute Russell viper venom confirm assay in an anticoagulation clinic population

Blood Coagulation and Fibrinolysis

Volumn 27, Issue 1, 2016, Pages 53-57

  McGlasson, David L ^a   Fritsma, George A ^b  

^a JBSA Lackland ^*  (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Anticoagulant agents; Dabigatran etexilate; Ecarin; Liquid chromatography; Mass spectrometry; Russell viper venom time; Thrombin time

Indexed keywords

DABIGATRAN; ANTICOAGULANT AGENT; ANTITHROMBIN;

AGED; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DILUTE RUSSELL VIPER VENOM CONFIRM ASSAY; DRUG BLOOD LEVEL; DRUG DETERMINATION; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; ANIMAL; BLOOD; BLOOD CLOTTING TEST; DABOIA RUSSELLII; MASS SPECTROMETRY;

AGED; ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; BLOOD COAGULATION TESTS; CHROMATOGRAPHY, LIQUID; DABIGATRAN; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; RUSSELL'S VIPER;

EID: 84952327102     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000382     Document Type: Article

References (16)

1. Tagarakis GI, Karangelis D, Daskalopoulos ME, Tsilimingas NB. Dabigatran: the anticoagulant we have long expected? Recent Pat Cardiovasc Drug Discov 2010; 5:223-226.
2. Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, et al. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation 2013; 128:237-243.
3. Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012; 5:480-486.
4. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation fr om the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013; 11:756-760.
5. Patriquin C, Crowther M. Chapter 26: antithrombotic agents. In Kitchens CS, Kessler CM, Konkle BA, editors. Consultative hemostasis and thrombosis, 3rd ed. Philadelphia: Elsevier; 2013.
6. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63:321-328.
7. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: anti thrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2-suppl):44S-88S.
8. Lind SE, Boyle ME, Fisher S, Is himoto J, Trujillo TC, Kiser TH. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples. Am J Clin Pathol 2014; 141:665-674.
9. Van de Werf F, Brueckmann M, Connolly SJ, Friedman J, Granger CB, Härtter S, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J 2012; 163:93-97.
10. Exner T, Ellwood L, Rubie J, Barancewicz A. Testing for new oral anticoagulants with LA-resistant Russells viper venom reagents. An in vitro study. Thromb Haemost 2013; 109:762-765.
11. McGlasson DL, Fritsma GA, Ezzell EE, Anderson NS. Meas uring dabigatran with the dilute Russell viper venom confirm assay in an anticoagulation clinic population. Abstract COA38. J Thromb Haemostas 2014; 12 (Suppl 1):106.
12. Exner T, Papadopoulos G, Koutts J. Use of a simplified dilute Russell's viper venom time (DRVVT) confirms heterogeneity among ' lupus anticoagulants' . Blood Coagul Fibrinolysis 1990; 1:259-266.
13. Douxfils J, Tamigniau A, Chatelain B, Chatelain C, Wallemacq P, Dogné JM, Mullier F. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 2013; 110: 723-731.
14. Fritsma GA, McGlasson DL. Quick guide to laboratory statistics and quality control. Washington, DC: AACC Press; 2012. pp. 20-23.
15. Froom P, Saffuri-Elias E, Rozenberg O, Barak M. The association of serum antiphospholipid antibodies and dilute Russell's viper venom times. J Clin Pathol 2014; 67:441-444.
16. Douxfils J, Classen J-F, Baudar J, Walbrecq S, Chatelain C, Chatelam B, et al. Dilute Russell viper venom time: a useful assay for the monitoring of direct oral anticoagulants in patients? 2013 Inter national Society on Thromb Haemost 2013; 11:290-1019; [Abs PB 4.52-1].